Risankizumab for the Treatment of the Patients with Moderate to Severe Plaque Psoriasis During a 24-Week Period: Real-Life Experience by Gönülal M, Balcı DD, Öztürkcan S

Subjects: Get full text

Effectiveness and Safety of Tildrakizumab in Psoriasis Patients Who Failed Anti-IL17 Treatment: A 28-Week Real-Life Study by Megna M, Ruggiero A, Tommasino N, Brescia C, Martora F, Cacciapuoti S, Potestio L

Subjects: Get full text

Long-Term Efficacy of Guselkumab in an Adolescent Hidradenitis Suppurativa Patients: A Case Report by Martora F, Battista T, Potestio L, Portarapillo A, Tommasino N, Megna M

Subjects: Get full text

Safety of interleukin inhibitors in patients with plaque psoriasis and history of neoplasms: a multicenter retrospective study – IL PSO (Italian landscape psoriasis) by Mario Valenti, Luciano Ibba, Sara Di Giulio, Luigi Gargiulo, Piergiorgio Malagoli, Anna Balato, Carlo G. Carrera, Paolo Dapavo, Eugenia V. Di Brizzi, Valentina Dini, Francesca Gaiani, Francesco Loconsole, Angelo V. Marzano, Matteo Megna, Alessandra Michelucci, Luca Potestio, Simone Ribero, Antonio Costanzo, Alessandra Narcisi

Subjects: “…Anti-IL-23…”
Get full text

Effectiveness of tildrakizumab 200 mg: an Italian multicenter study by Annunziata Dattola, Nicoletta Bernardini, Francesca Svara, Anna Balato, Giacomo Caldarola, Domenico D’Amico, Clara De Simone, Eugenia Veronica Di Brizzi, Maria Esposito, Claudia Giofrè, Domenico Giordano, Claudio Guarneri, Francesco Loconsole, Viviana Lora, Gaia Moretta, Diego Orsini, Severino Persechino, Concetta Potenza, Simone Ragonesi, Giovanni Pellacani, Ketty Peris, Maria Concetta Fargnoli, Antonio Giovanni Richetta

Subjects: Get full text

Risankizumab for the Treatment of Palmoplantar Pustular Psoriasis: A Report of Two Cases by Luigi Gargiulo, Carlo Alberto Vignoli, Giulia Pavia, Alessandra Narcisi, Antonio Costanzo, Chiara Perugini

Subjects: Get full text

Pharmacovigilance of Risankizumab in the Treatment of Psoriasis and Arthritic Psoriasis: Real-World Data from EudraVigilance Database by Fabrizio Calapai, Ilaria Ammendolia, Luigi Cardia, Mariaconcetta Currò, Gioacchino Calapai, Emanuela Esposito, Carmen Mannucci

Subjects: Get full text

Effectiveness and Safety After a Switch to Tildrakizumab: A Real World Multicenter Italian Study in Psoriasis by Eugenia Veronica Di Brizzi, Dario Buononato, Pierfrancesco Benvenuto, Giuseppe Argenziano, Rocco De Pasquale, Carmen Silvia Fiorella, Claudia Gioffrè, Maria Letizia Musumeci, Giovanni Palazzo, Leonardo Zichichi, Anna Balato

Subjects: Get full text

Anti-IL-17/23 Drugs for the Treatment of Moderate-to-Severe Hidradenitis Suppurativa in Patients With Concomitant Psoriasis: A Multicenter Retrospective Study by Luigi Gargiulo, Luciano Ibba, Alessandra Narcisi, Silvia Giordano, Carlo A. Maronese, Fabrizio Martora, Federica Repetto, Giovanni Paolino, Anna Balato, Martina Burlando, Paolo Dapavo, Valentina Dini, Claudio Guarneri, Angelo V. Marzano, Matteo Megna, Santo R. Mercuri, Antonio Costanzo, Mario Valenti

Subjects: Get full text

Efficacy and Safety of Tildrakizumab in a Patient with Chronic HBV Infection by Potestio L, Piscitelli I, Fabbrocini G, Martora F, Ruggiero A, Megna M

Subjects: Get full text

Rapid Remission of Sunburn-Induced Guttate Psoriasis with Guselkumab by Erin Bartholomew, Bo-Young Chung, Mitchell Davis, Samuel Yeroushalmi, Mimi Chung, Marwa Hakimi, Tina Bhutani, Wilson Liao

Subjects: Get full text

Adverse Events Associated With Anti-IL-23 Agents: Clinical Evidence and Possible Mechanisms by Yi Ru, Yi Ru, Xiaojie Ding, Xiaojie Ding, Ying Luo, Ying Luo, Hongjin Li, Xiaoying Sun, Mi Zhou, Yaqiong Zhou, Le Kuai, Le Kuai, Meng Xing, Meng Xing, Liu Liu, Liu Liu, Yue Luo, Yue Luo, Jiankun Song, Jiankun Song, Jiale Chen, Jiale Chen, Bin Li, Bin Li, Bin Li, Xin Li, Xin Li

Subjects: “…anti-IL-23…”
Get full text

Emerging Role of Biologic Drugs Targeting IL-17 and IL-23: Pityriasis Rubra Pilaris by Luca Potestio, Michela D’Agostino, Antonio Portarapillo, Valeria Esposito, Nello Tommasino, Antonia Salsano, Luigi Guerriero, Fabrizio Martora, Matteo Megna

Subjects: Get full text

A 3-Year Multicentric Study on Switching from Ustekinumab to Guselkumab in Partial Responders with Psoriasis—IL PSO (Italian Landscape Psoriasis) by Mario Valenti, Luciano Ibba, Ruggero Cascio Ingurgio, Piergiorgio Malagoli, Andrea Carugno, Marco Campoli, Carlo G. Carrera, Francesca M. Gaiani, Davide Strippoli, Federica Mola, Angelo V. Marzano, Nicola Zerbinati, Anna Minuti, Antonio Costanzo, Alessandra Narcisi

Subjects: Get full text

Efficacy and safety of tildrakizumab in elderly patients: real-world multicenter study (ESTER – study) by Diego Orsini, Giacomo Caldarola, Annunziata Dattola, Elena Campione, Nicoletta Bernardini, Pasquale Frascione, Clara De Simone, Antonio G. Richetta, Marco Galluzzo, Nevena Skroza, Chiara Assorgi, Emanuele Amore, Gennaro M. Falco, Ruslana Gaeta Shumak, Fabio Artosi, Giulia Maretti, Concetta Potenza, Luca Bianchi, Giovanni Pellacani, Ketty Peris, Claudio Bonifati, Dario Graceffa

Subjects: Get full text

Tildrakizumab for the Treatment of Moderate-to-Severe Psoriasis: Results from 52 Weeks Real-Life Retrospective Study by Ruggiero A, Fabbrocicni G, Cacciapuoti S, Potestio L, Gallo L, Megna M

Subjects: Get full text

Guselkumab, Risankizumab, and Tildrakizumab in the Management of Hidradenitis Suppurativa: A Review of Existing Trials and Real-Life Data by Martora F, Scalvenzi M, Battista T, Fornaro L, Potestio L, Ruggiero A, Megna M

Subjects: Get full text

Prospective Real-Life Multicenter Study of Tildrakizumab 200 mg for Moderate-to-Severe Psoriasis: Who Is the Ideal Patient? by Eugenia Veronica Di Brizzi, Stefano Caccavale, Roberta Di Caprio, Francesco Cusano, Rocco De Pasquale, Valeria Falcomatà, Caterina Foti, Claudia Giofrè, Emanuela Gubinelli, Giampiero Mazzocchetti, Massimiliano Nicolini, Giovanni Palazzo, Leonardo Pescitelli, Rosa Valentina Puca, Oriele Sarno, Anna Balato

Subjects: Get full text

Biologics Versus JAK Inhibitors. Part II: Risk of Infections. A Narrative Review by Miguel Mansilla-Polo, Daniel Morgado-Carrasco

Subjects: Get full text

Risankizumab as an effective therapeutic option in severe psoriasis unsuccessfully treated with therapies involving anti- TNF-α and anti-IL-17 by Michał Adamczyk, Dorota Krasowska

Subjects: Get full text